210 related articles for article (PubMed ID: 24901404)
21. PAX8 and PAX2 immunostaining facilitates the diagnosis of primary epithelial neoplasms of the male genital tract.
Tong GX; Memeo L; Colarossi C; Hamele-Bena D; Magi-Galluzzi C; Zhou M; Lagana SM; Harik L; Oliver-Krasinski JM; Mansukhani M; Falcone L; Hibshoosh H; O'Toole K
Am J Surg Pathol; 2011 Oct; 35(10):1473-83. PubMed ID: 21934480
[TBL] [Abstract][Full Text] [Related]
22. PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison.
Ozcan A; Liles N; Coffey D; Shen SS; Truong LD
Am J Surg Pathol; 2011 Dec; 35(12):1837-47. PubMed ID: 21989345
[TBL] [Abstract][Full Text] [Related]
23. PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck.
Bishop JA; Sharma R; Westra WH
Hum Pathol; 2011 Dec; 42(12):1873-7. PubMed ID: 21663937
[TBL] [Abstract][Full Text] [Related]
24. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
25. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics.
Kernochan LE; Garcia RL
J Natl Compr Canc Netw; 2009 May; 7(5):550-6; quiz 557. PubMed ID: 19460280
[TBL] [Abstract][Full Text] [Related]
26. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
27. Carcinosarcoma arising from high-grade serous carcinoma of the ovary without estrogen receptor, WT-1, and PAX8 immunoreactivity.
Harada N; Nobuhara I; Haruta N; Higashiura Y; Fujii H; Yamao K; Shimada K
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):110-114. PubMed ID: 35181017
[TBL] [Abstract][Full Text] [Related]
28. Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case.
Watanabe M; Shimizu K; Kato H; Imai H; Nakano H; Sugawa M; Shiraishi T
Gynecol Oncol; 2001 Sep; 82(3):563-7. PubMed ID: 11520156
[TBL] [Abstract][Full Text] [Related]
29. A subset of solitary fibrous tumors express nuclear PAX8 and PAX2: a potential diagnostic pitfall.
McDaniel AS; Palanisamy N; Smith SC; Robinson DR; Wu YM; Chinnaiyan AM; McHugh JB; Greenson JK; Kunju LP
Histol Histopathol; 2016 Feb; 31(2):223-30. PubMed ID: 26404914
[TBL] [Abstract][Full Text] [Related]
30. Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.
Mikami Y; Hata S; Kiyokawa T; Manabe T
Mod Pathol; 2002 Sep; 15(9):923-30. PubMed ID: 12218209
[TBL] [Abstract][Full Text] [Related]
31. Carcinosarcoma (malignant mixed müllerian tumor) of the uterus with a rhabdoid tumor component. An immunohistochemical, ultrastructural, and immunoelectron microscopic case study.
Mount SL; Lee KR; Taatjes DJ
Am J Clin Pathol; 1995 Feb; 103(2):235-9. PubMed ID: 7856569
[TBL] [Abstract][Full Text] [Related]
32. L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition.
Versluis M; Plat A; de Bruyn M; Matias-Guiu X; Trovic J; Krakstad C; Nijman HW; Bosse T; de Bock GH; Hollema H
Virchows Arch; 2018 Nov; 473(5):591-598. PubMed ID: 30140948
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors.
Buza N; Tavassoli FA
Int J Gynecol Pathol; 2009 Nov; 28(6):514-21. PubMed ID: 19851197
[TBL] [Abstract][Full Text] [Related]
34. Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma.
Nishimura I; Ohishi Y; Oda Y; Kishimoto J; Yasunaga M; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
Virchows Arch; 2011 Jan; 458(1):85-94. PubMed ID: 21046151
[TBL] [Abstract][Full Text] [Related]
35. Malignant mixed müllerian tumor of the uterus. Features favoring its origin from a common cell clone and an epithelial-to-mesenchymal transformation mechanism of histogenesis.
Guarino M; Giordano F; Pallotti F; Polizzotti G; Tricomi P; Cristofori E
Tumori; 1998; 84(3):391-7. PubMed ID: 9678624
[TBL] [Abstract][Full Text] [Related]
36. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract.
Albadine R; Schultz L; Illei P; Ertoy D; Hicks J; Sharma R; Epstein JI; Netto GJ
Am J Surg Pathol; 2010 Jul; 34(7):965-9. PubMed ID: 20463571
[TBL] [Abstract][Full Text] [Related]
37. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.
Liliac L; Carcangiu ML; Canevari S; Căruntu ID; Ciobanu Apostol DG; Danciu M; Onofriescu M; Amălinei C
Rom J Morphol Embryol; 2013; 54(1):17-27. PubMed ID: 23529305
[TBL] [Abstract][Full Text] [Related]
38. Malignant mixed Müllerian tumors of the uterus. An immunohistochemical study.
Auerbach HE; LiVolsi VA; Merino MJ
Int J Gynecol Pathol; 1988; 7(2):123-30. PubMed ID: 3294195
[TBL] [Abstract][Full Text] [Related]
39. The immunohistochemical profile of malignant mixed müllerian tumor. Overlap with endometrial adenocarcinoma.
Meis JM; Lawrence WD
Am J Clin Pathol; 1990 Jul; 94(1):1-7. PubMed ID: 1694389
[TBL] [Abstract][Full Text] [Related]
40. COX-2 expression in uterine carcinosarcoma.
Menczer J; Schreiber L; Sukmanov O; Kravtsov V; Berger E; Golan A; Levy T
Acta Obstet Gynecol Scand; 2010; 89(1):120-5. PubMed ID: 19900134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]